ライフサイエンスコーパス: Waldenstrom macroglobulinemia

1 th treatment-naive, or relapse or refractory Waldenstrom macroglobulinemia.

2 a, 2 had classic Hodgkin lymphoma, and 2 had Waldenstrom macroglobulinemia.

3 ght-chain amyloidosis, multiple myeloma, and Waldenstrom macroglobulinemia.

4 ic leukemia (CLL), mantle cell lymphoma, and Waldenstrom macroglobulinemia.

5 from patients with mantle cell lymphoma and Waldenstrom macroglobulinemia.

6 ificance, smoldering plasma cell myeloma, or Waldenstrom macroglobulinemia.

7 of MyD88, which is mutated in a fraction of Waldenstrom macroglobulinemia.

8 and safety of acalabrutinib in patients with Waldenstrom macroglobulinemia.

9 as splenic marginal zone B-cell lymphoma or Waldenstrom macroglobulinemia.

10 the advances observed in the pathogenesis of Waldenstrom macroglobulinemia.

11 ironment) that regulate tumor progression in Waldenstrom macroglobulinemia.

12 rapeutic targeting, such as interleukin-6 in Waldenstrom macroglobulinemia.

13 patients with heavily pretreated MM (22) or Waldenstrom macroglobulinemia (3) were administered seli

14 ymphoma overall, and a 3-fold higher risk of Waldenstrom macroglobulinemia, a low-grade lymphoma.

15 The records of patients with Waldenstrom macroglobulinemia and OCT documentation of s

16 Four patients (8 eyes) with Waldenstrom macroglobulinemia and serous retinal detachm

17 with splenic marginal zone lymphoma, 29 with Waldenstrom macroglobulinemia, and 57 with B-cell chroni

18 Multiple myeloma and Waldenstrom macroglobulinemia are incurable hematologic

19 ell lymphoma, diffuse large B-cell lymphoma, Waldenstroms macroglobulinemia, chronic lymphocytic leuk

20 Adjusted P values for non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, cryoglobulinemia, and thy

21 early universal in multiple myeloma, whereas Waldenstrom macroglobulinemia generally does not harbor

22 enetic abnormalities in multiple myeloma and Waldenstrom macroglobulinemia have implications for dise

23 of 6q is identified in 50% of patients with Waldenstrom macroglobulinemia, however.

24 cally the standard of care for patients with Waldenstrom macroglobulinemia; however, infectious and h

25 Histologic transformation of Waldenstrom macroglobulinemia (HT-WM) carries a poor pro

26 d in 17 patients (relative risk [RR], 14.8), Waldenstrom macroglobulinemia in 6 (RR, 262), primary am

27 Waldenstrom macroglobulinemia is a distinct low-grade ly

28 Waldenstrom macroglobulinemia is a similar disease with

29 Inflammatory form of Waldenstrom macroglobulinemia (iWM) predicts outcomes af

30 ording to the 6th International Workshop for Waldenstrom Macroglobulinemia (IWWM) and the modified 3r

31 = 2.9; 1.9-4.3), lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL/WM; RR = 4.0; 1.5-11)

32 ype diffuse large B-cell lymphoma and 90% of Waldenstrom macroglobulinemia, making it conceptually at

33 ies, including chronic lymphocytic leukemia, Waldenstrom macroglobulinemia, mantle cell lymphoma, and

34 ry, acute myeloid leukemia/myelofibrosis and Waldenstrom macroglobulinemia/myeloma.

35 Risks for non-Hodgkin lymphoma (n = 1359), Waldenstrom macroglobulinemia (n = 165), and cryoglobuli

36 ic leukemia (Richter transformation; n = 7), Waldenstrom macroglobulinemia (n = 4), and marginal zone

37 patients (36%), with the most frequent being Waldenstrom macroglobulinemia (n = 9, 20%).

38 Observations: Waldenstrom macroglobulinemia remains a rare, incurable

39 Following profiling, Waldenstrom macroglobulinemia samples clustered with chr

40 Profiling performed after separation of Waldenstrom macroglobulinemia samples into populations w

41 B-cell morphology revealed that plasma cell Waldenstrom macroglobulinemia samples most closely resem

42 ion and survival of patients with smoldering Waldenstrom macroglobulinemia (SWM).

43 r refractory (at least one previous therapy) Waldenstrom macroglobulinemia that required treatment, a

44 en with systemic treatment of the underlying Waldenstrom macroglobulinemia, the visual prognosis was

45 tients with iNHL (follicular, marginal zone, Waldenstrom macroglobulinemia) treated with chemotherapy

46 he bone marrow biopsy specimen, diagnosis of Waldenstrom macroglobulinemia was established, and compu

47 cil to Fludarabine in Patients With Advanced Waldenstrom Macroglobulinemia) was undertaken in 101 cen

48 tions, and myelokathexis (WHIM) syndrome and Waldenstrom macroglobulinemia, we demonstrated that muta

49 (IgM) class, which progresses to lymphoma or Waldenstrom macroglobulinemia, whereas IgA and IgG MGUS

50 We included patients with Waldenstrom macroglobulinemia (WM) and a radiologic and/

51 ell lymphoproliferative disorders, including Waldenstrom macroglobulinemia (WM) and chronic lymphocyt

52 Treatment options for patients with Waldenstrom macroglobulinemia (WM) and closely related d

53 both in the understanding of the biology of Waldenstrom macroglobulinemia (WM) and in therapeutic op

54 significance (MGUS), multiple myeloma (MM), Waldenstrom macroglobulinemia (WM) and light chain AL am

55 YD88 L265P somatic mutation in patients with Waldenstrom macroglobulinemia (WM) and provide insight i

56 Familial aggregation of Waldenstrom macroglobulinemia (WM) and related B-cell di

57 265P somatic mutation is highly prevalent in Waldenstrom macroglobulinemia (WM) and supports malignan

58 Familial aggregation of Waldenstrom macroglobulinemia (WM) cases, and the cluste

59 Waldenstrom macroglobulinemia (WM) cells present with in

60 mbination led to synergistic cytotoxicity in Waldenstrom macroglobulinemia (WM) cells that was mediat

61 cal evaluation of investigational agents for Waldenstrom macroglobulinemia (WM) has been limited by t

62 rom other IgM-producing gammopathies such as Waldenstrom macroglobulinemia (WM) has not been well cha

63 ormation about the molecular pathogenesis of Waldenstrom macroglobulinemia (WM) has significantly adv

64 Patients with Waldenstrom macroglobulinemia (WM) have disparate outcom

65 elated clones in the blood of a patient with Waldenstrom macroglobulinemia (WM) indicates the functio

66 Waldenstrom macroglobulinemia (WM) is a B-cell disorder

67 Waldenstrom macroglobulinemia (WM) is a B-cell malignanc

68 Waldenstrom macroglobulinemia (WM) is a B-cell malignanc

69 Waldenstrom macroglobulinemia (WM) is a B-cell malignanc

70 Waldenstrom macroglobulinemia (WM) is a B-cell neoplasm

71 Waldenstrom macroglobulinemia (WM) is a distinct B-cell

72 Waldenstrom macroglobulinemia (WM) is a distinct B-cell

73 Waldenstrom macroglobulinemia (WM) is a distinct B-cell

74 Waldenstrom macroglobulinemia (WM) is a lymphoid neoplas

75 Waldenstrom macroglobulinemia (WM) is a proliferative di

76 Waldenstrom macroglobulinemia (WM) is a rare, lymphoplas

77 Waldenstrom macroglobulinemia (WM) is an incurable low-g

78 Waldenstrom macroglobulinemia (WM) is an incurable low-g

79 Waldenstrom macroglobulinemia (WM) is an incurable low-g

80 Waldenstrom macroglobulinemia (WM) is an incurable lymph

81 Waldenstrom macroglobulinemia (WM) is an uncommon lympho

82 Current information on Waldenstrom macroglobulinemia (WM) is based on retrospec

83 Waldenstrom macroglobulinemia (WM) is characterized by w

84 Waldenstrom macroglobulinemia (WM) is preceded by asympt

85 Multilevel genetic characterization of Waldenstrom macroglobulinemia (WM) is required to improv

86 tiomic analysis on a series of MYD88-mutated Waldenstrom macroglobulinemia (WM) patients and identifi

87 ing thalidomide and rituximab in symptomatic Waldenstrom macroglobulinemia (WM) patients naive to eit

88 or kappaB activity and is present in >90% of Waldenstrom macroglobulinemia (WM) patients.

89 nical models, the role of these molecules in Waldenstrom macroglobulinemia (WM) remains poorly unders

90 The genetic basis for Waldenstrom macroglobulinemia (WM) remains to be clarifi

91 4 years), 34 (71%) progressed to symptomatic Waldenstrom macroglobulinemia (WM) requiring treatment,

92 A whole exome-sequencing study of Waldenstrom macroglobulinemia (WM) suggested a high freq

93 igh response rates and durable remissions in Waldenstrom macroglobulinemia (WM) that are impacted by

94 The survival of patients with Waldenstrom macroglobulinemia (WM) varies enormously.

95 large B-cell lymphoma (ABC DLBCL) and BCWM.1 Waldenstrom macroglobulinemia (WM) xenografted mice with

96 gnificance of IL-21 has not been examined in Waldenstrom macroglobulinemia (WM), a B-cell lymphoma ch

97 For Waldenstrom macroglobulinemia (WM), a distinct subtype o

98 Waldenstrom macroglobulinemia (WM), a distinctive subtyp

99 portant information on the cell of origin in Waldenstrom macroglobulinemia (WM), a longstanding puzzl

100 ed as appropriate agents in the treatment of Waldenstrom macroglobulinemia (WM), a lymphoplasmacytic

101 hemokine receptor type 4 (CXCR4) mutation in Waldenstrom macroglobulinemia (WM), a marker of tumor ag

102 Waldenstrom macroglobulinemia (WM), an IgM-associated ly

103 resent in approximately 95% of patients with Waldenstrom macroglobulinemia (WM), as well as other B-c

104 phoma (MZL), Mantle Cell Lymphoma (MCL), and Waldenstrom macroglobulinemia (WM), between 01-Jan-2008

105 has revealed recurring somatic mutations in Waldenstrom macroglobulinemia (WM), including MYD88 (95%

106 eviously untreated symptomatic patients with Waldenstrom macroglobulinemia (WM), most of which were o

107 derstand the molecular changes that occur in Waldenstrom macroglobulinemia (WM), we employed antibody

108 r approach and its use has been validated in Waldenstrom macroglobulinemia (WM), where bortezomib has

109 ic of several B cell malignancies, including Waldenstrom macroglobulinemia (WM), where elevated IgM i

110 Waldenstrom macroglobulinemia (WM), which has an immunog

111 ling in malignant lymphoplasmacytic cells in Waldenstrom macroglobulinemia (WM).

112 inhibition has not yet been investigated in Waldenstrom macroglobulinemia (WM).

113 MYD88 and CXCR4 mutations are common in Waldenstrom macroglobulinemia (WM).

114 (95%-97%) and CXCR4 (30%-40%) are common in Waldenstrom macroglobulinemia (WM).

115 nesis of hematologic malignancies, including Waldenstrom macroglobulinemia (WM).

116 nubrutinib versus ibrutinib in patients with Waldenstrom macroglobulinemia (WM).

117 has revealed recurring somatic mutations in Waldenstrom macroglobulinemia (WM).

118 ations including MYD88, CXCR4, and ARID1A in Waldenstrom macroglobulinemia (WM).

119 tigate and report its aberrant activation in Waldenstrom macroglobulinemia (WM).

120 ictate clinical presentation and survival in Waldenstrom macroglobulinemia (WM).

121 atic mutations in MYD88 (L265P) and CXCR4 in Waldenstrom macroglobulinemia (WM).

122 eviously untreated symptomatic patients with Waldenstrom macroglobulinemia (WM).

123 inostat in patients with relapsed/refractory Waldenstrom macroglobulinemia (WM).

124 fective treatment approach for patients with Waldenstrom macroglobulinemia (WM).

125 brand syndrome is described in patients with Waldenstrom macroglobulinemia (WM).

126 ytic lymphoma (LPL), including IgM-secreting Waldenstrom macroglobulinemia (WM).

127 rolimus in patients with relapsed/refractory Waldenstrom macroglobulinemia (WM).

128 tuximab in patients with relapsed/refractory Waldenstrom macroglobulinemia (WM).

129 t of rapamycin (mTOR) complex 1 inhibitor in Waldenstrom macroglobulinemia (WM).

130 otherapy in previously treated patients with Waldenstrom macroglobulinemia (WM).

131 BDR) in patients with symptomatic, untreated Waldenstrom macroglobulinemia (WM).

132 study examining fludarabine and rituximab in Waldenstrom macroglobulinemia (WM).

133 ned significance (IgM-MGUS) and asymptomatic Waldenstrom macroglobulinemia (WM; aWM) are precursor co

134 of patients with lymphoplasmacytic lymphoma (Waldenstrom macroglobulinemia [WM]), being either absent

135 xome sequencing data in 34 subjects (23 with Waldenstrom macroglobulinemia [WM], 6 with IgM monoclona